BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29617381)

  • 1. Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial.
    Wali RK; Bianchi L; Kupfer S; De La Cruz M; Jovanovic B; Weber C; Goldberg MJ; Rodriguez LM; Bergan R; Rubin D; Tull MB; Richmond E; Parker B; Khan S; Roy HK
    PLoS One; 2018; 13(4):e0193544. PubMed ID: 29617381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.
    Higurashi T; Hosono K; Endo H; Takahashi H; Iida H; Uchiyama T; Ezuka A; Uchiyama S; Yamada E; Ohkubo H; Sakai E; Maeda S; Morita S; Natsumeda Y; Nagase H; Nakajima A
    BMC Cancer; 2012 Sep; 12():413. PubMed ID: 22992267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
    Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
    Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
    Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
    Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.
    Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
    BMC Cancer; 2020 Aug; 20(1):770. PubMed ID: 32807113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial.
    Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
    BMC Cancer; 2020 Oct; 20(1):1043. PubMed ID: 33121471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia.
    Sinicrope FA; Viggiano TR; Buttar NS; Song LMWK; Schroeder KW; Kraichely RE; Larson MV; Sedlack RE; Kisiel JB; Gostout CJ; Kalaiger AM; Patai ÁV; Della'Zanna G; Umar A; Limburg PJ; Meyers JP; Foster NR; Yang CS; Sontag S
    Cancer Prev Res (Phila); 2021 May; 14(5):573-580. PubMed ID: 33648940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyethylene glycol-mediated colorectal cancer chemoprevention: roles of epidermal growth factor receptor and Snail.
    Wali RK; Kunte DP; Koetsier JL; Bissonnette M; Roy HK
    Mol Cancer Ther; 2008 Sep; 7(9):3103-11. PubMed ID: 18790788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.
    Limburg PJ; Mahoney MR; Ziegler KL; Sontag SJ; Schoen RE; Benya R; Lawson MJ; Weinberg DS; Stoffel E; Chiorean M; Heigh R; Levine J; Della'Zanna G; Rodriguez L; Richmond E; Gostout C; Mandrekar SJ; Smyrk TC;
    Cancer Prev Res (Phila); 2011 Feb; 4(2):259-69. PubMed ID: 21209397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
    Gordon M; Naidoo K; Akobeng AK; Thomas AG
    Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.
    Roy HK; Turzhitsky V; Wali R; Radosevich AJ; Jovanovic B; Della'Zanna G; Umar A; Rubin DT; Goldberg MJ; Bianchi L; De La Cruz M; Bogojevic A; Helenowski IB; Rodriguez L; Chatterton R; Skripkauskas S; Page K; Weber CR; Huang X; Richmond E; Bergan RC; Backman V
    Gut; 2017 Feb; 66(2):285-292. PubMed ID: 26503631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.
    Gillen DL; Meyskens FL; Morgan TR; Zell JA; Carroll R; Benya R; Chen WP; Mo A; Tucker C; Bhattacharya A; Huang Z; Arcilla M; Wong V; Chung J; Gonzalez R; Rodriguez LM; Szabo E; Rosenberg DW; Lipkin SM
    Cancer Prev Res (Phila); 2015 Mar; 8(3):222-30. PubMed ID: 25604134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Combination of Prebiotics Galacto-Oligosaccharides and Inulin-Inhibited Aberrant Crypt Foci Formation and Biomarkers of Colon Cancer in Wistar Rats.
    Qamar TR; Syed F; Nasir M; Rehman H; Zahid MN; Liu RH; Iqbal S
    Nutrients; 2016 Aug; 8(8):. PubMed ID: 27490566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyethylene glycol, unique among laxatives, suppresses aberrant crypt foci, by elimination of cells.
    Taché S; Parnaud G; Van Beek E; Corpet DE
    Scand J Gastroenterol; 2006 Jun; 41(6):730-6. PubMed ID: 16716974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukotriene Receptor Antagonist Therapy for the Chemoprevention of Human Rectal Aberrant Crypt Foci: Nonrandomized, Open-Label, Controlled Trial.
    Higurashi T; Ashikari K; Tamura S; Saigusa Y; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Kessoku T; Hosono K; Yoneda M; Nakajima A
    Cancer Prev Res (Phila); 2022 Oct; 15(10):661-668. PubMed ID: 36083855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of colon carcinogenesis by polyethylene glycol: suppression of epithelial proliferation via modulation of SNAIL/beta-catenin signaling.
    Roy HK; Kunte DP; Koetsier JL; Hart J; Kim YL; Liu Y; Bissonnette M; Goldberg M; Backman V; Wali RK
    Mol Cancer Ther; 2006 Aug; 5(8):2060-9. PubMed ID: 16928827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.
    Drew DA; Chin SM; Gilpin KK; Parziale M; Pond E; Schuck MM; Stewart K; Flagg M; Rawlings CA; Backman V; Carolan PJ; Chung DC; Colizzo FP; Freedman M; Gala M; Garber JJ; Huttenhower C; Kedrin D; Khalili H; Kwon DS; Markowitz SD; Milne GL; Nishioka NS; Richter JM; Roy HK; Staller K; Wang M; Chan AT
    Trials; 2017 Feb; 18(1):50. PubMed ID: 28143522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, double-blind, randomized, placebo-controlled trial comparing the efficacy of polyethylene glycol versus polyethylene glycol combined with topical diltiazem for treating anal fissure in children.
    Alshehri A; Barghouthi R; Albanyan S; Alayed M; Alsubaie H; Alhayyan R; Alzahem A; Altokhais T; Albassam A; Aljazaeri A
    J Pediatr Surg; 2020 Oct; 55(10):2017-2021. PubMed ID: 32057442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osmotic and stimulant laxatives for the management of childhood constipation.
    Gordon M; Naidoo K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2012 Jul; (7):CD009118. PubMed ID: 22786523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDs.
    Pereira MA
    Adv Exp Med Biol; 1999; 470():55-63. PubMed ID: 10709674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.